Vonoprazan for Helicobacter Pylori Eradication in Adolescents
Key facts
- Who runs it
- Alexandria University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 242 people enrolled
- Started
- 1 Jan 2024
- Ended
- 1 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan
- Amoxicillin
- Clarithromycin
- Esomeprazole
- Record updated
- 28 August 2024
Who can take part
- Age
- 10 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Children in the age group (10-18 years), both genders, referred with dyspeptic complaints such as heartburn, dyspepsia, nausea, and epigastric pain
- Who is positive for H. Pylori infection by a standardized diagnostic test
- Pediatric patients with a clinical, laboratory, and endoscopic diagnosis of H.P.-positive gastritis and the other conditions necessary for H.P. eradication according to the Maastricht V consensus report
Who cannot take part
- previous attempts to eradicate H.P
- Use of antibiotics, acid-suppression, bismuth, or probiotics 4 weeks before enrollment
- allergy to any of the drugs used in the study
- Children with conditions that affect medication absorption e.g. celiac or Crohn's disease
- Liver or kidney failure
- symptoms suggestive of functional disorders
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior eradication rates (VONTAPE trial).
The 2 groups in the trial
- Vonoprazan-based triple therapyTreatment being tested
Vonoprazan tablets 20 mg twice daily plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\] The triple combination will be given for 14 days
Treatment: Vonoprazan, Amoxicillin, and Clarithromycin
- Proton pump-based triple therapy "standard triple therapy"Existing treatment, for comparison
Esomeprazole tablets \[20 mg/day if \< 30 kg and 40 mg/daily if ≥ 30 kg\] on two divided daily doses plus Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose 2 g\] plus Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose 1 g\] The triple combination will be given for 14 days
Treatment: Amoxicillin, Clarithromycin, and Esomeprazole
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Vonoprazan-based Triple Therapy vs. Standard Triple Therapy for Helicobacter Pylori Eradication in Adolescents: A Randomized, Double-blinded Controlled Trial
- Publications
- Record updated
- 28 August 2024